Bayer Faces a Pivotal Week: Supreme Court Hearing and Dividend Date Collide

Bayer stock drops 6% ahead of Supreme Court Roundup arguments and a token €0.11 dividend, but analysts see 24% upside if legal risks ease.

The coming days will test Bayer’s resilience on multiple fronts. On Monday, the US Supreme Court hears oral arguments in the Roundup litigation — a moment that could reshape the company’s legal landscape — while the stock simultaneously goes ex-dividend for a token payout of €0.11 per share. The convergence of these events puts the German pharmaceutical and agricultural giant under a microscope.

A Minimal Payout with Maximum Significance

Bayer’s dividend, paid on Wednesday, is deliberately meagre. At Friday’s closing price of €38.50, the yield amounts to barely 0.3%. Management is hoarding cash for two pressing needs: debt reduction and legal provisions. The company has set aside €5 billion this year alone for ongoing litigation, while net debt fell 8.5% to just under €30 billion by the end of 2025.

The ex-dividend date marks a technical adjustment, but the real action shifts immediately to the Supreme Court. Bayer has been lugging the Roundup liability since its Monsanto acquisition in 2018. Tens of thousands of plaintiffs allege the weedkiller causes cancer. A favourable ruling from Washington could open the door to a comprehensive settlement and remove one of the biggest overhangs on the balance sheet.

Chart Sends Mixed Signals

The stock has lost momentum in recent sessions. Over the past seven trading days, shares have shed 6.33%, closing Friday at €38.50 — below both the 50-day moving average of €40.50 and the 100-day line of €40.59. The latter breach is considered a classic technical sell signal.

Yet the longer-term picture remains intact. The 200-day average at €34.37 continues to support the medium-term uptrend, and the stock still shows a 71% gain over twelve months. From the 52-week high of €49.17, the current price sits roughly 22% lower. The relative strength index stands at 46.8 — neutral territory, not oversold.

Analysts See Upside Beyond the Noise

Despite the recent chart deterioration, major investment houses maintain a bullish stance. Barclays rates the stock “Overweight” with a €48 target. Goldman Sachs, UBS and JP Morgan all recommend buying. Only Deutsche Bank holds at “Neutral”. The consensus price target of €47.63 implies roughly 24% upside from current levels.

The message from the Street is clear: the legal risk is already baked into the share price. If the Roundup cloud lifts, the re-rating could be substantial.

What to Watch This Week

All eyes are on the Supreme Court. Should the justices signal a narrowing of plaintiffs’ avenues to sue, the €40 mark could quickly come back into play. An ambiguous or unfavourable outcome would keep the pressure on.

Beyond the courtroom, Bayer reports first-quarter results on 12 May. Management targets currency-adjusted revenue of €45-47 billion for full-year 2026, with analysts pencilling in €46.4 billion. Free cash flow remains deeply negative, with the company forecasting a deficit of up to €2.5 billion. A strong operational performance could ease the recent downward pressure.

For now, the macro backdrop — including the Federal Reserve’s decision on 29 April — is secondary. Bayer’s fate this week hinges on Washington, not on interest rates.